On Agenda item 11.7 – Access to medicines and vaccines, KEI offers the following comments on the transparency resolution. 1. Transparency should not be controversial. Policy makers and the public need to have better evidence in order to support policies… Continue Reading →
The WHO has scheduled two information negotiations on the WHA transparency resolution, in Geneva, for May 7 and 10. Below is the revised version of the proposed resolution, that will be discussed at these two meetings. Improving the transparency of… Continue Reading →
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading →
On 1 February 2019, Dr. Giulia Grillo, Italy’s Minister of Health, sent a letter to Dr. Tedros Adhanom Ghebreyesus, the Director General of the World Health Organization (WHO), with an attached “first draft” of a resolution on “Improving the transparency… Continue Reading →
The WHO Essential Medicines List is a major WHO tool used to expand access to medicines. In 2017, the WHO issued the 20th Essential Medicines List (EML) which was the 40th anniversary of the list. The WHO is currently in… Continue Reading →
KEI/HAI Interventions HAI/KEI intervention at the WHA69 on the Framework of Engagement with Non-State Actors HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement Interventions by Member States WHA 69: Colombian Minister of Health Calls on WHO… Continue Reading →
Interventions made by KEI WHA70: Statement of Knowledge Ecology International – CEWG follow up WHA70: Statement of Knowledge Ecology International on antimicrobial resistance WHA70: Statement of Knowledge Ecology International on review of the GSPOA-PHI WHA70: Statement of Knowledge Ecology International:… Continue Reading →
Interventions made by KEI WHA71: KEI statement on the Draft thirteenth general programme of work, 2019–2023 WHA71: KEI intervention on the Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to… Continue Reading →
After lengthy negotiations, on Friday, 26 January 2018 the World Health Organization’s Executive Board approved a decision to reinvigorate the Organization’s work program on innovation and access to medicines. Here are two quotes from KEI on the decision: James Love,… Continue Reading →
The World Health Organization’s (WHO) Executive Board is expected to discuss agenda item 3.8 on Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018 the either… Continue Reading →